Advertisement
Singapore markets closed

  • Straits Times Index

    3,307.90
    -6.15 (-0.19%)
     

  • S&P 500

    5,308.13
    +4.86 (+0.09%)
     

  • Dow

    39,806.77
    -196.82 (-0.49%)
     

  • Nasdaq

    16,794.88
    +108.91 (+0.65%)
     

  • Bitcoin USD

    71,285.67
    +4,282.25 (+6.39%)
     

  • CMC Crypto 200

    1,542.56
    +54.01 (+3.63%)
     

  • FTSE 100

    8,391.31
    -32.89 (-0.39%)
     

  • Gold

    2,424.50
    -14.00 (-0.57%)
     

  • Crude Oil

    78.46
    -1.34 (-1.68%)
     

  • 10-Yr Bond

    4.4370
    +0.0170 (+0.38%)
     

  • Nikkei

    38,946.93
    -122.75 (-0.31%)
     

  • Hang Seng

    19,220.62
    -415.60 (-2.12%)
     

  • FTSE Bursa Malaysia

    1,622.09
    -5.41 (-0.33%)
     

  • Jakarta Composite Index

    7,186.04
    -80.65 (-1.11%)
     

  • PSE Index

    6,633.66
    -49.12 (-0.74%)
     

Here's What Key Metrics Tell Us About Qiagen (QGEN) Q1 Earnings

Zacks Equity Research
·3-min read

For the quarter ended March 2024, Qiagen (QGEN) reported revenue of $458.8 million, down 5.5% over the same period last year. EPS came in at $0.46, compared to $0.53 in the year-ago quarter.

The reported revenue represents a surprise of +0.73% over the Zacks Consensus Estimate of $455.5 million. With the consensus EPS estimate being $0.44, the EPS surprise was +4.55%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

ADVERTISEMENT

Here is how Qiagen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Sales by Product Groups- Diagnostic solutions- QIAstat-Dx: $25 million versus $23.82 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +19.1% change.

  • Sales by Product Groups- Diagnostic solutions- QuantiFERON: $101 million versus $105.61 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +9.8% change.

  • Sales by Product Groups- Genomics / NGS: $55 million versus $50.95 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a 0% change.

  • Sales by Product Groups- Other: $11 million versus $11.67 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -35.3% change.

  • Sales by Product Groups- PCR / Nucleic acid amplification: $68 million versus $70.87 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -11.7% change.

  • Sales by Product Groups- Diagnostic solutions- NeuMoDx: $9 million versus $11.44 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -30.8% change.

  • Sales by Product Groups- Sample technologies: $155 million versus $146.53 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -10.4% change.

  • Sales by Product Groups- Diagnostic solutions: $170 million versus the three-analyst average estimate of $174.25 million. The reported number represents a year-over-year change of +4.3%.

  • Revenue- Life Sciences: $215 million versus $208.53 million estimated by two analysts on average.

  • Sales by Product Groups- Diagnostic solutions- Other: $35 million versus the two-analyst average estimate of $35.07 million.

  • Revenue- Molecular Diagnostics: $244 million compared to the $247.55 million average estimate based on two analysts. The reported number represents a change of -2.4% year over year.

View all Key Company Metrics for Qiagen here>>>

Shares of Qiagen have returned -3.1% over the past month versus the Zacks S&P 500 composite's -2% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

QIAGEN N.V. (QGEN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research